(KRYS) Krystal Biotech - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 7.624m USD | Total Return: 58.3% in 12m

Genetic Medicines, Skin Treatments, Eye Treatments
Total Rating 56
Safety 85
Buy Signal 0.86
Biotechnology
Industry Rotation: -5.8
Market Cap: 7.62B
Avg Turnover: 64.6M USD
ATR: 3.73%
Peers RS (IBD): 48.8
Risk 5d forecast
Volatility41.4%
Rel. Tail Risk-4.89%
Reward TTM
Sharpe Ratio1.35
Alpha28.70
Character TTM
Beta1.172
Beta Downside1.431
Drawdowns 3y
Max DD42.26%
CAGR/Max DD1.07
EPS (Earnings per Share) EPS (Earnings per Share) of KRYS over the last years for every Quarter: "2021-03": -0.67, "2021-06": -0.74, "2021-09": -0.7, "2021-12": -0.95, "2022-03": -0.99, "2022-06": -1.1, "2022-09": -1.17, "2022-12": -1.25, "2023-03": -1.76, "2023-06": -1.25, "2023-09": -0.69, "2023-12": 0.3, "2024-03": 0.03, "2024-06": 0.53, "2024-09": 0.91, "2024-12": 1.53, "2025-03": 1.1962, "2025-06": 1.29, "2025-09": 2.66, "2025-12": 1.7, "2026-03": 0,
EPS CAGR: 26.48%
EPS Trend: 84.4%
Last SUE: -2.51
Qual. Beats: 0
Revenue Revenue of KRYS over the last years for every Quarter: 2021-03: 0, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 8.556, 2023-12: 42.143, 2024-03: 45.25, 2024-06: 70.284, 2024-09: 83.841, 2024-12: 91.139, 2025-03: 88.183, 2025-06: 96.042, 2025-09: 97.8, 2025-12: 107.105, 2026-03: null,
Rev. CAGR: 137.21%
Rev. Trend: 91.0%
Last SUE: 0.24
Qual. Beats: 0

Warnings

No concerns identified

Tailwinds

Pullback Retrace

Description: KRYS Krystal Biotech

Krystal Biotech, Inc. (KRYS) is a commercial-stage biotechnology company. It focuses on genetic medicines for diseases with unmet medical needs in the United States. The biotechnology sector often involves lengthy and costly research and development phases.

The company commercializes VYJUVEK for dystrophic epidermolysis bullosa (DEB). It also has a pipeline of genetic medicine candidates, including treatments for ocular complications of DEB, neurotrophic keratitis, cystic fibrosis, Hailey-Hailey disease, solid tumors, dynamic wrinkles, anti-PD-1 relapsed/refractory conditions, Alpha-1 antitrypsin deficiency, and aesthetic skin conditions. Gene therapy is a specialized area within biotechnology, focusing on modifying genes to treat or prevent disease.

Krystal Biotech was founded in 2016 and is based in Pittsburgh, Pennsylvania. To further explore the companys financial health, consider reviewing its detailed financials on ValueRay.

Headlines to Watch Out For
  • VYJUVEK sales drive revenue growth
  • Pipeline development expands future revenue potential
  • Regulatory approvals critical for new therapies
  • Clinical trial results impact stock valuation
  • Manufacturing costs influence profitability
Piotroski VR‑10 (Strict) 4.0
Net Income: 204.8m TTM > 0 and > 6% of Revenue
FCF/TA: 0.14 > 0.02 and ΔFCF/TA 2.88 > 1.0
NWC/Revenue: 236.9% < 20% (prev 220.3%; Δ 16.54% < -1%)
CFO/TA 0.15 > 3% & CFO 200.9m > Net Income 204.8m
Net Debt (-818.5m) to EBITDA (167.8m): -4.88 < 3
Current Ratio: 9.95 > 1.5 & < 3
Outstanding Shares: last quarter (30.0m) vs 12m ago 0.23% < -2%
Gross Margin: 92.61% > 18% (prev 0.93%; Δ 9.17k% > 0.5%)
Asset Turnover: 32.57% > 50% (prev 27.52%; Δ 5.05% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM)
Altman Z'' 5.73
A: 0.69 (Total Current Assets 1.02b - Total Current Liabilities 102.9m) / Total Assets 1.33b
B: 0.02 (Retained Earnings 24.2m / Total Assets 1.33b)
C: 0.13 (EBIT TTM 161.3m / Avg Total Assets 1.19b)
D: 0.22 (Book Value of Equity 25.3m / Total Liabilities 114.2m)
Altman-Z'' Score: 5.73 = AAA
Beneish M -2.98
DSRI: 0.91 (Receivables 127.4m/104.7m, Revenue 389.1m/290.5m)
GMI: 1.01 (GM 92.61% / 93.09%)
AQI: 0.79 (AQ_t 0.11 / AQ_t-1 0.14)
SGI: 1.34 (Revenue 389.1m / 290.5m)
TATA: 0.00 (NI 204.8m - CFO 200.9m) / TA 1.33b)
Beneish M-Score: -2.98 (Cap -4..+1) = A
What is the price of KRYS shares? As of April 14, 2026, the stock is trading at USD 267.41 with a total of 240,861 shares traded.
Over the past week, the price has changed by +2.14%, over one month by +8.15%, over three months by -8.40% and over the past year by +58.32%.
Is KRYS a buy, sell or hold? Krystal Biotech has received a consensus analysts rating of 4.64. Therefore, it is recommended to buy KRYS.
  • StrongBuy: 8
  • Buy: 2
  • Hold: 1
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the KRYS price?
Analysts Target Price 314 17.4%
Krystal Biotech (KRYS) - Fundamental Data Overview as of 14 April 2026
P/E Trailing = 37.8655
P/E Forward = 44.843
P/S = 19.5921
P/B = 6.2513
Revenue TTM = 389.1m USD
EBIT TTM = 161.3m USD
EBITDA TTM = 167.8m USD
Long Term Debt = 9.34m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.77m USD (from shortTermDebt, last quarter)
Debt = 9.34m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -818.5m USD (recalculated: Debt 9.34m - CCE 827.8m)
Enterprise Value = 6.81b USD (7.62b + Debt 9.34m - CCE 827.8m)
 Interest Coverage Ratio = unknown (Ebit TTM 161.3m / Interest Expense TTM 0.0)
 EV/FCF = 36.02x (Enterprise Value 6.81b / FCF TTM 188.9m)
FCF Yield = 2.78% (FCF TTM 188.9m / Enterprise Value 6.81b)
FCF Margin = 48.55% (FCF TTM 188.9m / Revenue TTM 389.1m)
Net Margin = 52.64% (Net Income TTM 204.8m / Revenue TTM 389.1m)
Gross Margin = 92.61% ((Revenue TTM 389.1m - Cost of Revenue TTM 28.8m) / Revenue TTM)
Gross Margin QoQ = 89.81% (prev 94.21%)
Tobins Q-Ratio = 5.10 (Enterprise Value 6.81b / Total Assets 1.33b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 9.34m)
Taxrate = 21.0% (US default 21%)
NOPAT = 127.4m (EBIT 161.3m * (1 - 21.00%))
Current Ratio = 9.95 (Total Current Assets 1.02b / Total Current Liabilities 102.9m)
Debt / Equity = 0.01 (Debt 9.34m / totalStockholderEquity, last quarter 1.22b)
Debt / EBITDA = -4.88 (Net Debt -818.5m / EBITDA 167.8m)
Debt / FCF = -4.33 (Net Debt -818.5m / FCF TTM 188.9m)
Total Stockholder Equity = 1.10b (last 4 quarters mean from totalStockholderEquity)
RoA = 17.14% (Net Income 204.8m / Total Assets 1.33b)
RoE = 18.69% (Net Income TTM 204.8m / Total Stockholder Equity 1.10b)
RoCE = 14.60% (EBIT 161.3m / Capital Employed (Equity 1.10b + L.T.Debt 9.34m))
RoIC = 11.63% (NOPAT 127.4m / Invested Capital 1.10b)
WACC = 10.09% (E(7.62b)/V(7.63b) * Re(10.10%) + D(9.34m)/V(7.63b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 10.10% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.95%
[DCF] Terminal Value 61.82% ; FCFF base≈161.0m ; Y1≈105.7m ; Y5≈48.3m
[DCF] Fair Price = 51.68 (EV 702.8m - Net Debt -818.5m = Equity 1.52b / Shares 29.4m; r=10.09% [WACC]; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 84.42 | EPS CAGR: 26.48% | SUE: -2.51 | # QB: 0
Revenue Correlation: 90.96 | Revenue CAGR: 137.2% | SUE: 0.24 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.72 | Chg7d=-0.025 | Chg30d=+0.017 | Revisions Net=-1 | Analysts=6
EPS current Year (2026-12-31): EPS=7.73 | Chg7d=+0.000 | Chg30d=-0.097 | Revisions Net=+0 | Growth EPS=+13.1% | Growth Revenue=+38.1%
EPS next Year (2027-12-31): EPS=10.58 | Chg7d=+0.000 | Chg30d=-0.276 | Revisions Net=-2 | Growth EPS=+36.8% | Growth Revenue=+28.6%
[Analyst] Revisions Ratio: -1.00 (0 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 7.5% (Discount Rate 10.1% - Earnings Yield 2.6%)
[Growth] Growth Spread = +23.9% (Analyst 31.3% - Implied 7.5%)
External Resources
Dataroma Stockcircle